Acronym: OSTEOproSPINE 
Name: Novel Bone Regeneration Drug Osteogrow: Therapeutic Solution for Lumbar Back Pain 
Project status: From: 2018-01-01 To: 2022-12-31 (Execution)
Contract number: 779340 
Action line: SC-1 
Type (Programme): HORIZON 2020 
Instrument: RIA 
Project cost: 702.750,00 EUR
Project funding: 6.004.152,00 EUR
Project coordinator
Organisation Name: Sveučilište u Zagrebu Medicinski fakultet 
Organisation adress: Šalata 3, Zagreb 
Organisation country: Croatia 
Contact person name: Slobodan Vukičević 
Contact person email: Email 
Croatian partner
Organisation name: Medicinski fakultet 
Organisation address: Šalata 3, Zagreb 
Contact person name: Slobodan Vukičević
Contact person tel:
4920046  Contact person fax:  
Contact person e-mail:  
Organisation nameCountry
Short description of project
  OSTEOproSPINE is a novel bone regeneration therapy composed of OSTEOGROW (recombinant human bone morphogenetic protein 6 [rhBMP6] delivered in autologous peripheral blood coagulum) reinforced with allograft (a compression resistant matrix). OSTEOproSPINE is designed to guide the formation of new bone at extra-skeletal site and replace autograft harvested from patient’s iliac crest for the fusion of lumbar vertebrae. By generating new bone, OSTEOproSPINE will restore the spine’s weight bearing function, reduce the severity of back pain and improve the success rate of posterolateral spinal fusion surgery. The program consortium of 13 partners from 6 EU member states has been assembled to conduct a Phase II, randomised, patient and evaluator-blinded clinical trial of OSTEOproSPINE. Four clinical centers will enrol 180 patients suffering from degenerative disc disease to assess OSTEOproSPINE efficacy and safety in comparison with standard of care (autograft) and Osteogrow. A positive outcome of the proposed trial will confirm OSTEOproSPINE’s potential to form a functioning new bone in human and by this restore the spine’s function and improve the quality of life in patients with degenerative disc disorders using the ground principle of regenerative medicine: “provide the correct molecular signals to a population of presumptive cells in a permissive microenvironment”.  
Short description of the task performed by Croatian partner


Design by: M. Mačinković

(C)opyright by Sveučilište u Zagrebu,